Grifols stock up: Q3 revenue tops estimates as immunoglobulin sales drive growth
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Grifols reported third-quarter revenue above expectations on Monday, driven by growth in its Biopharma business, and confirmed its full-year guidance. Shares are up 4% following the news. Still guessing which stocks will beat the market? Our AI portfolio updates…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRevenue above consensus and confirmed guidance lifted the stock, up about 4%.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Grifols reported third quarter revenue of €2.04 billion, above the €1.98 billion consensus.
- 02Net profit rose 27.9% to €162 million.
- 03Adjusted EBITDA increased 9.8% at constant currency to €538 million.
- 04Full-year guidance was confirmed.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets